Placebo to telcagepant

DRUG2 trials

Conditions

Angina PectorisCalcitonin Gene-related Peptide ReceptorCerebrovascular AccidentCoronary Heart DiseaseHeart DiseaseMigraine DisordersPeripheral Vascular DiseasesTIA (Transient Ischemic Attack)

Phase 1

A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

CompletedNCT01294709

Merck Sharp & Dohme LLCAngina Pectoris, Calcitonin Gene-related Peptide Receptor, Coronary Heart Disease

Start: 2008-02-12End: 2009-03-13Updated: 2018-10-18

Phase 3

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

CompletedNCT00662818

Merck Sharp & Dohme LLCCerebrovascular Accident, Heart Disease, Migraine Disorders +3

Start: 2008-03-17End: 2009-09-02Updated: 2018-10-19

Placebo to telcagepant

Sponsors

Conditions

Phase 1

Phase 3